Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Veregen versus placebo for superficial basal cell carcinoma
NL-OMON40522Phase 2Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2014
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in basal cell carcinoma (BCC) comparing Veregen with Placebo (2 arms). Primary endpoint: Histological clearance of target tumor. Started Nov 2014; status: active, not recruiting.
02
Drugs
sinecatechins
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON40522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40522.